Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
View: Text | PDF
Research Article Inflammation Oncology

Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers

  • Text
  • PDF
Abstract

Carcinomas are common in humans but rare among closely related “great apes.” Plausible explanations, including human-specific genomic alterations affecting the biology of sialic acids, are proposed, but causality remains unproven. Here, an integrated evolutionary genetics-phenome-transcriptome approach studied the role of SIGLEC12 gene (encoding Siglec-XII) in epithelial transformation and cancer. Exogenous expression of the protein in cell lines and genetically engineered mice recapitulated approximately 30% of the human population in whom the protein is expressed in a form that cannot bind ligand because of a fixed, homozygous, human-universal missense mutation. Siglec-XII–null cells/mice recapitulated the remaining approximately 70% of the human population in whom an additional polymorphic frameshift mutation eliminates the entire protein. Siglec-XII expression drove several pro-oncogenic phenotypes in cell lines and increased tumor burden in mice challenged with chemical carcinogen and inflammation. Transcriptomic studies yielded a 29-gene signature of Siglec-XII–positive disease and when used as a computational tool for navigating human data sets, pinpointed with surprising precision that SIGLEC12 expression (model) recapitulates a very specific type of colorectal carcinomas (disease) that is associated with mismatch-repair defects and inflammation, disproportionately affects European Americans, and carries a favorable prognosis. They revealed a hitherto-unknown evolutionary genetic mechanism for an ethnic/environmental predisposition of carcinogenesis.

Authors

Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh

×

Figure 5

SIGLEC12 expression induces gene expression in polyps at risk of progression to CRCs.

Options: View larger image (or click on image) Download as PowerPoint
SIGLEC12 expression induces gene expression in polyps at risk of progres...
(A) An overview of experimental design for the induction of Siglec-XII expression by serial administration of tamoxifen followed by carcinogenesis protocol consisting of a single administration of AOM and 4 cycles of DSS. On day 87, mouse colon tumors were harvested for RNA-Seq analysis. (B) Heatmap shows the z-normalized expression pattern of upregulated differentially expressed genes (DEGs) in Siglec-XII–expressing cohort. Red on the x axis highlights Ptpn18 gene. (C) Plot showing the fold-enrichment of various biological processes from the Gene Ontology (GO) database. (D and E) Violin plots display the StepMiner normalized composite scores of the DEGs (in B) in control versus Siglec-XII samples at baseline (day 12; D) (collected within 1 week after tamoxifen administration) and Caco-2 pcDNA3.1(-) and Siglec-XII–Caco-2 (E). (F) Violin plots display the StepMiner normalized composite scores of the DEGs (in B) in patient tissues from 3 independent cohorts (National Center for Biotechnology Information [NCBI] Gene Expression Omnibus [GEO] GSE76987, GSE117606, and GSE117607). R, right; L, left; SSA, sessile serrated adenoma; Adj., adjacent. (G) Violin plots display the StepMiner normalized composite scores of the DEGs (in B) in laser-microdissected adenomatous tissues from polyps that progressed to cancers (cancer-adjacent polyps [CAPs]) versus those that did not (cancer-free polyps [CFPs]) (33–35). Statistics: P values in each violin plot (D–G) are based on 2-tailed Welch’s t test between comparator groups. P values for survival plots were determined by log-rank test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts